Make your own free website on Tripod.com

Welcome to Dr. Hamid Sanatinia's Virtual Headquarters
Unknown Primary

Home

Should we treat or not???
Performace Status
Antiemetics
Growth Factors
Calculations
Chemo Precautions
TOXICITY CRITERIA
Antidepressants
Chemoprotection
MESNA
Dexrazoxane
Radioprotectants
Hypercalcemia of malignancy
Mucositis
Neutropenic Fever
Palliative Care
Radiation Oncology
<<<<<<<<<>>>>>>>>>
ALL
AML
Anal
Bladder Cancer
Brain Cancer
Breast (risk category)
Breast (adjuvant)
Breast (metastatic)
Breast (Xeloda)
Breast (hormonal)
Breast Cancer Genetics
Carcinoid
CLL
CML
COLON CANCER
Endometrial
Esophagous
Gastric
Gestational Trophoblastic Disease
Germ Cell (Ovary)
Hairy Cell Leukemia
Head/Neck
Head/Neck: ChemoRT abstracts
Head/Neck: Larynx
Head/Neck:Nasopharyngeal
Hodgkins
Islet Cell Tumors
Kidney
Liver
LUNG, NSC
Stage III Unresectable NSC Lung Cancer
Lung, SC
Lymphoma, Aggressive
Lymphoma, AIDS
Lymphoma, Burkitts
Lymphoma, CNS
Lymphoma, Cutaneous
Lymphoma, Indolent
Lymphoma, MALT
Lymphoma, Mantle cell
Lymphoma, Mediastinal B-Cell
Lymphoma, Refractory NHL
Melanoma
Mesothelioma
Multiple Myeloma
MDS
NHL
Ovarian
Pancreas
Prostate
Prostate (Hormonal)
Rectal Cancer
Sarcoma
Sarcoma, Ewing's
Sarcoma, Osteogenic
Skeletal Metastasis
Testicular Cancer
Thymoma
Thyroid Cancer
Waldenstrom's
Unknown Primary
<<<<<<<<<>>>>>>>>>
Molecular Genetics
Oncogenes, the list!
Immunoperoxidase stains
Tumor Markers
Bleomycin
Cisplatin
Etoposide
Ifosfamide
Methotrexate
Temazolamide
Mechanism of Action
Dose Modifications (Renal)
Dose Modifications (hepatic)
MDR

Poorly differentiated neoplasms
Adenocarcinoma
Squamous carcinoma
Poorly differentiated carcinoma

------------------------------------------------------------

Poorly differentiated neoplasms

R/O lymphoma, melanoma, sarcoma,...
34-66% of poorly differentiated neoplasms were found to be lymphomas after further path studies.
Poorly differentiated carcinomas account for the remaining tumors in this group.
------------------------------------------------------------
Adenocarcinoma of unknown primary site

Accounts for 70% of unknown primary cases


WOMEN WITH PERITNOEAL CARCINOMATOSIS: Treat as stage III ovarian CA ie Carbo+Taxol
Long term remission in 15-20% of patients.
WOMEN WITH AXILLARY NODE METASTASIS: Check for ER/PR receptors. If met isolated to the axillary node, it should be treated as stage II breast cancer with potential for cure. When mastectomy is performed, an occult breast ca is identified in 44-82% of patients.
MEN WITH SKELETAL METASTASIS: Suspect metastatic prostate ca. especially if skeletal met is the dominant site and the cells are blastic. Stain it for PSA. Obtain PSA levels. Also suspect kidney, thyroid, colon, and bronchus.
SINGLE METASTIC LESION: Resect if technically feasable. If poorly differentiated carcinoma, then consider platinum. Also consider XRT to the region.

------------------------------------------------------------
Squamous Carcinoma of Unknown Primary

..

Enter content here

Enter supporting content here